Stockreport

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

Assembly Biosciences, Inc.  (ASMB) 
Last assembly biosciences, inc. earnings: 3/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.assemblybio.com/investor-relations
PDF – ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days – – Half-life of approximately 20 days supports once-weekly or o [Read more]